Eric R. Olson - 17 Jul 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: SYRS
Reported as of: 17 Jul 2023
Net transaction value: -$2,412
SEC form: 4
Accepted by SEC: 18 Jul 2023, 20:27:08 UTC
Prior SEC filing: 04 Apr 2023
Source filing: View source filing
Reporting owner signature: /s/ Todd Rosenthal, as attorney-in-fact

Key filing fact

Eric R. Olson filed Form 4 for Syros Pharmaceuticals, Inc. (SYRS) on 18 Jul 2023.

Key facts

This page summarizes Eric R. Olson's Form 4 filing for Syros Pharmaceuticals, Inc. (SYRS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Jul 2023, 20:27.

Change

Previous filing in this sequence was filed on 04 Apr 2023.
Current net transaction value: -$2,412.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SYRS transaction

Common Stock

Sale

Transaction value: $2,412
Shares: -689
Change %: -9.4%
Price: $3.50
Shares after: 6,661
Date: 17 Jul 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

The sale reported on this Form 4 was effected pursuant to a trading plan adopted on March 31, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.